Skip to main content

Table 1 Clinical characteristics of patients with tigecycline-associated coagulation dysfunction events

From: Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database

  No. of coagulation-dyfunction in tigecycline (%) No. of other AEs in tigecycline (%)
Gender
 Male 125 (56.05) 520 (40.19)
 Female 69 (30.94) 501 (38.72)
 Missing 29 (13.00) 273 (21.10)
Age
  < 65 69 (30.94) 470 (36.32)
  ≥ 65 98 (43.95) 360 (27.82)
 Missing 56 (25.11) 464 (35.86)
Reporter
 Healthcare workers 130 (58.30) 787 (60.82)
 Non-health care workers 83 (37.22) 457 (35.32)
 Unknown 10 (4.48) 50 (3.86)
Year
 2005–2010 51 (22.87) 420 (32.46)
 2011–2015 71 (31.84) 418 (32.30)
 2016–2020 101 (45.29) 456 (35.24)
Outcome
 Death 45 (20.18) 340 (26.28)
 Life-threatening 28 (12.56) 61 (4.71)
 Disability 0 (0.00) 16 (1.24)
 Hospitalization 35 (15.70) 308 (23.80)
 Other serious 107 (47.98) 405 (31.30)
 Required intervention 1 (0.45) 4 (0.31)
 Missing 7 (3.14) 160 (12.36)
Dosing regimen
 Loading dose 28 (12.56) 86 (6.64)
 Non-loading dose 121 (54.26) 305 (23.57)
 Standard maintenance dosea 111 (49.78) 481 (37.17)
 High maintenance dosec 34 (15.25) 124 (9.58)
Time to event 10 (IQR 6.75–13)  
Total 223 1294
  1. a Standard maintenance dose means the dose of tigecycline administered at 100 mg/d
  2. b High maintenance dose means the dose of tigecycline administered at 200 mg/d or higher